EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
A. Pieter Kappetein
Ad J.J.C. Bogers
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Birim, O.
Right arrow Articles by Bogers, A. J.J.C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Birim, O.
Right arrow Articles by Bogers, A. J.J.C.

Eur J Cardiothorac Surg 2005;28:759-762
© 2005 Elsevier Science NL

Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer{star}

Özcan Birim, A. Pieter Kappetein * , Ad J.J.C. Bogers

Department of Cardio-Thoracic Surgery, Erasmus MC Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands

Received 23 March 2005; received in revised form 14 June 2005; accepted 29 June 2005.

* Corresponding author. Tel.: +31 10 4635412; fax: +31 10 4633993. (Email: a.kappetein{at}erasmusmc.nl).

Objective: To evaluate the impact of the Charlson comorbidity index on long-term survival in nonsmall cell lung cancer surgery and determine whether this index is a better predictor of long-term survival than individual comorbid conditions. Methods: From January 1989 to December 2001, 433 (340 men, 93 women) consecutive curative resections for nonsmall cell lung cancer were performed. Each patient was preoperatively assessed according to the Charlson comorbidity index. Survival curves were estimated by the Kaplan–Meier method. Risk factors for overall and disease free survival were determined by univariate and multivariate Cox regression analysis. Results: The patients ranged in age from 37 to 82 years, with a mean age of 65 years. Hospital mortality was 3.7%. Five-year overall and disease free survival was 45 and 43%, respectively. Among patients with Charlson comorbidity grade 0, 5-year overall survival was 52%, among patients with Charlson comorbidity grade 1–2 it was 48%, and among patients with Charlson comorbidity grade ≥3 it was 28%. Univariate analysis showed that male gender, age, congestive heart failure, chronic pulmonary disease, Charlson comorbidity index, clinical stage, pathological stage, and type of resection were significantly associated with an impaired survival. Multivariate analysis showed that age (relative risk, 1.02; 95% confidence interval, 1.01–1.03), Charlson comorbidity grade 1–2 (relative risk, 1.4; 95% confidence interval, 1.0–1.8), Charlson comorbidity grade ≥3 (relative risk, 2.2; 95% confidence interval, 1.5–3.1), bilobectomy (relative risk, 1.7; 95% confidence interval, 1.2–2.5), pneumonectomy (relative risk, 1.5; 95% confidence interval, 1.1–2.0), pathological stage IB (relative risk, 1.5; 95% confidence interval, 1.1–2.2), IIB (relative risk, 1.9; 95% confidence interval, 1.2–3.0), IIIA (relative risk, 1.9; 95% confidence interval, 1.1–3.1), IIIB (relative risk, 2.8; 95% confidence interval, 1.2–6.8), and IV (relative risk, 12.4; 95% confidence interval, 3.2–48.2), were associated with an impaired survival. Conclusions: The Charlson comorbidity index is a better predictor of survival than individual comorbid conditions in nonsmall cell lung cancer surgery. We recommend the use of a validated comorbidity index in the selection of patients for NSCLC surgery.

Key Words: Charlson comorbidity index • Comorbidity • Lung cancer • Surgery • Survival




This article has been cited by other articles:


Home page
JCOHome page
L. E. Jones and C. C. Doebbeling
Beyond the Traditional Prognostic Indicators: The Impact of Primary Care Utilization on Cancer Survival
J. Clin. Oncol., December 20, 2007; 25(36): 5793 - 5799.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
C.-Y. Wang, Y.-S. Lin, C. Tzao, H.-C. Lee, M.-H. Huang, W.-H. Hsu, and H.-S. Hsu
Comparison of Charlson comorbidity index and Kaplan Feinstein index in patients with stage I lung cancer after surgical resection
Eur. J. Cardiothorac. Surg., December 1, 2007; 32(6): 877 - 881.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
T.-E. Strand, H. Rostad, R. A M Damhuis, and J. Norstein
Risk factors for 30-day mortality after resection of lung cancer and prediction of their magnitude
Thorax, November 1, 2007; 62(11): 991 - 997.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
D. Trousse, F. Barlesi, A. Loundou, A. M. Tasei, C. Doddoli, R. Giudicelli, P. Astoul, P. Fuentes, and P. Thomas
Synchronous multiple primary lung cancer: An increasing clinical occurrence requiring multidisciplinary management
J. Thorac. Cardiovasc. Surg., May 1, 2007; 133(5): 1193 - 1200.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.